Cardinal Health Inc
Health Care
Cardinal Health Inc (CAH) Stock News
The latest CAH headlines and market coverage — 6 recent stories, updated throughout the day.
- Zacks Investment Research·
Cardinal Health (CAH) Laps the Stock Market: Here's Why
Cardinal Health (CAH) gained 2.41% in recent trading, outperforming the S&P 500. The prescription drug distributor is expected to report earnings of $2.92 per share on November 5, 2026, representing 14.51% year-over-year growth, with revenue projected at $66.96 billion. The stock holds a Zacks Rank #2 (Buy) rating, though it trades at a premium valuation with a Forward P/E of 19.75 compared to its industry average of 17.67.
- Zacks Investment Research·Neutral
Cardinal Health (CAH) Stock Moves -1.64%: What You Should Know
Cardinal Health (CAH) closed down 1.64% and is expected to report EPS of $2.92 (up 14.51% YoY) with revenue of $66.96 billion (up 4.6% YoY). The stock holds a Zacks Rank #3 (Hold) with a Forward P/E of 17.99, trading at a premium to its industry average. The Medical-Dental Supplies industry ranks in the top 44% of all industries.
- Zacks Investment Research·Neutral
Cardinal (CAH) Is Considered a Good Investment by Brokers: Is That True?
While Cardinal Health (CAH) has a strong average brokerage recommendation of 1.39 (Strong Buy equivalent) from 18 firms, the article cautions that broker recommendations are often overly optimistic due to vested interests. The Zacks Rank system rates CAH as a #3 (Hold), citing unchanged earnings estimates of $12.55 for the current year, suggesting the stock may perform in line with the broader market in the near term.
- Zacks Investment Research·
Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?
Cardinal Health expects fiscal 2027 IRA pricing changes to create similar revenue headwinds as 2026, but management aims to preserve compensation and maintain profitability through distribution agreements and operational efficiency. Peers BrightSpring and CVS Health also face IRA-related revenue pressure but are offsetting impacts through operational improvements and specialty pharmacy growth.
- GlobeNewswire Inc.·
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
Crinetics Pharmaceuticals announced positive Phase 2 trial results for atumelnant, an oral ACTH receptor antagonist for treating congenital adrenal hyperplasia (CAH). The drug demonstrated sustained androgen reductions while enabling patients to lower glucocorticoid supplementation to physiologically normal levels. Additional Phase 1b/2a data in ACTH-dependent Cushing's syndrome showed rapid cortisol reduction. The company is advancing atumelnant into late-phase clinical development with Phase 3 trials already underway.
- GlobeNewswire Inc.·
CAHI Honours The Honourable Don Boudria for Leadership in Animal Health
The Canadian Animal Health Institute (CAHI) announced its 2026 Annual Awards, presenting the Industry Leadership Award to former Cabinet Minister Don Boudria for his contributions to advancing animal health policy, and the Chair's Award to Dr. Arman Panah from Virbac for his leadership in regulatory modernization and industry collaboration.